Assessment of the risk of needlestick injuries associated with intravitreal injections

Retina

Volumn 34, Issue 4, 2014, Pages 781-784

  Shah, Sanket U ^a   Koenig, Michael J ^a   Dacquay, Yann ^a   Mozayan, Arash ^a   Hubschman, Jean Pierre ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADHESION; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; GLOVE; HEALTH SURVEY; HUMAN; NEEDLESTICK INJURY; NORMAL HUMAN; OPHTHALMOLOGIST; PACKAGING; PHARMACY; RISK ASSESSMENT; SYRINGE; UNITED STATES;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROSS-SECTIONAL STUDIES; DRUG COMPOUNDING; DRUG LABELING; HEALTH SURVEYS; HUMANS; INTRAVITREAL INJECTIONS; NEEDLESTICK INJURIES; OFF-LABEL USE; OPHTHALMOLOGY; QUESTIONNAIRES; RISK ASSESSMENT; SYRINGES; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897577795     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182a2f523     Document Type: Article

References (12)

1. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-S19.
2. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
3. Ford JA, Elders A, Shyangdan D, et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic mac-ular oedema: an indirect comparison in a systematic review. BMJ 2012;345:e5182.
4. Amoaku W, Pearce I, Browning A. Guidelines for Intravitreal Injections Procedure 2009. London, UK: Scientific Department, The Royal College of Ophthalmologists; 2009. Available at: www.rcophth.ac.uk/core/core-picker/ download.asp?id=167. Accessed May 30, 2013.
5. Bourla DH, Wirthlin RS, Bourla N, et al. Risk for eye splash injury during administration of intraocular injections: a study of retina specialists and fellows. Retina 2007;27:609-612.
6. Ciulla TA, Schnizlein-Bick CT, Danis RP, et al. Comparison of intraocular to plasma HIV-1 viral burden in patients with cytomegalovirus retinitis. Am J Ophthalmol 1999;127: 221-223.
7. FDA Approval for Bevacizumab. Silver Spring, MD: National Cancer Institute; January 23, 2013. Available at: http://www. cancer.gov/cancertopics/ druginfo/fda-bevacizumab. Accessed April 24, 2013.
8. Compliance Policy Guide. Chapter 4-Human Drugs. Subchapter 460-Pharmacy Issues. CPG Section 460.200: Pharmacy Compounding. Rockville, MD: Food and Drug Administration; 2002. Available at: http://www.fda.gov/ICECI/ComplianceManuals/ CompliancePolicyGuidanceManual/ucm074398.htm. Accessed April 24, 2013.
9. Compliance Policy Guide. Chapter 4-Human Drugs. Subchap-ter 430-Labeling and Repackaging. CPG Section 430.200: Repacking of Drug Products-Testing/ Examination under CGMPs. Rockville, MD: Food and Drug Administration; 2002. Available at: http://www.fda.gov/ICECI/ComplianceMa-nuals/ CompliancePolicyGuidanceManual/ucm074378.htm. Accessed April 24, 2013.
10. The special risks of pharmacy compounding. Available at: http://www.fda.gov/forconsumers/consumerupdates/ucm107836.htm. Accessed April 24, 2013.
11. Public Health Service, Food and Drug Administration. Warning Letter FLA-12-37. Available at: http://www.fda.gov/ICECI/EnforcementActions/ WarningLetters/2012/ucm317190.htm. Accessed April 24, 2013.
12. Yang L, Mullan B. Reducing needle stick injuries in healthcare occupations: an integrative review of the literature. ISRN Nurs 2011;2011:315432.